New drugs will reach patients sooner as a result of a new agreement between the United States and the European Union.
New drugs will reach patients sooner as a result of a new agreement between the United States and the European Union.
The Mutual Recognition Act removes various regulatory barriers for a wide range of products, including pharmaceuticals.
The agreement was developed primarily by the U.S. Food and Drug Administration, the U.S. Department of Commerce and the European Commission, a governing office of the European Union.
According to the agreement, the United States and participating European countries will recognize each others' inspections of pharmaceutical manufacturing facilities. This agreement will reduce costs for governments and manufacturers and ultimately translate into fewer delays in the availability of new medicines.
Previously, inspectors from each jurisdiction had to inspect every factory where an imported drug was manufactured.
"At a time when patients everywhere are waiting for cures for AIDS, Alzheimer's, cancer and a host of other diseases, this agreement will help get new treatments to patients fast," said Alan Holmer, president of the Pharmaceutical Research and Manufacturers of America, in support of the cooperative effort.
"The money saved by avoiding duplication of effort can be used to increase research on cures for currently incurable diseases," Holmer said. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.